Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

Blood (2024) 143 (2): 118–123.

https://doi.org/10.1182/blood.2023020621

Published: 2024

Includes: Supplemental data

Journal Articles

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Sara K. Silbert, Cynthia Harrison, D. Nathan Biery, Alexandra Semchenkova, Elena Zerkalenkova, Anna Alonso-Saladrigues, Kaylyn Utley, Ibrahim Aldoss, Liping Zhao, Sneha Fernandes, Jeremy D. Rubinstein, Naomi Torres Carapia, Bill H. Chang, Anant Vatsayan, Barbara De Moerloose, Holly L. Pacenta, Dennis John Kuo, Gabriele Escherich, Benjamin J. Lee, Michele S. Redell, Mandi R. Fitzjohn, Daniel P. Larson, Nicolas Duployez, Raymund S. Cuevo, Rui Rochelle He, David Dickens, Firas El Chaer, Kelly Reed, Matthias Wolfl, Sunil S. Raikar, Süreyya Savaşan, Latika Puri, Zhubin J. Gahvari, Aimee C. Talleur, Hisham Abdel-Azim, Aghiad Chamdin, Marlie R.M. Provost, Vanessa A. Fabrizio, Kerstin Mezger, Alexandra McLean Stevens, Emily M. Hsieh, Hao-Wei Wang, Constance M. Yuan, Ulrich A. Duffner, Jing Pan, Sara Ghorashian, Susana Rives, Chloe Hoang, Kara L. Davis, Elad Jacoby, Alexander Popov, Adam Lamble, Nirali N. Shah

Blood (2023) 142 (Supplement 1): 4202.

https://doi.org/10.1182/blood-2023-182293

Published: 2023

Journal Articles

A Single Centre Cohort Study of Monitoring B Cell Populations in the Bone Marrow and Peripheral Blood Post Tisagenlecleucel Therapy of Relapsed/Refractory Acute Lymphoblastic Leukaemia

Blood (2023) 142 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2023-182730

Published: 2023

Journal Articles

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Vaishali Dulobdas, Amy A Kirkwood, Fabio Serpenti, Brijesh Gautama, Aikaterini Panapoulou, Sumantha Gabriel, Ram Malladi, Jessica Pealing, Denise Bonney, Emma Nicholson, Caroline Besley, Sara Ghorashian, Elizabeth Davies, Jackie Chappell, Anne Black, Tobias Menne, Maeve O'Reilly, Robin Sanderson, Sridhar Chaganti

Blood (2023) 142 (Supplement 1): 495.

https://doi.org/10.1182/blood-2023-178834

Published: 2023

Journal Articles

Routine Whole Genome Sequencing for All Children with Hematological Malignancies Defines a New Standard of Care - Data of the First 152 Cases from the NHS England Genomic Medicine Service

Blood (2023) 142 (Supplement 1): 3656.

https://doi.org/10.1182/blood-2023-186025

Published: 2023

Journal Articles

Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure

Blood (2022) 140 (Supplement 1): 2408–2410.

https://doi.org/10.1182/blood-2022-162863

Published: 2022

Journal Articles

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Blood (2022) 140 (Supplement 1): 10352–10354.

https://doi.org/10.1182/blood-2022-164879

Published: 2022

Journal Articles

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 3268–3270.

https://doi.org/10.1182/blood-2022-162565

Published: 2022

Journal Articles

Siglec-6 CAR T: magic bullet for a moving target

Sara Ghorashian, Martin Pule

Blood (2021) 138 (19): 1786–1787.

https://doi.org/10.1182/blood.2021013184

Published: 2021

Journal Articles

Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia Administered Inotuzumab Pre CAR-T Therapy

Blood (2021) 138 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2021-148820

Published: 2021

Journal Articles

A High Sensitivity aCD22 CAR Combined with aCD19 CAR to Generate Dual Targeting CAR T Cells for the Treatment of r/r B-ALL

Blood (2021) 138 (Supplement 1): 1710.

https://doi.org/10.1182/blood-2021-152655

Published: 2021

Journal Articles

ALL Maintenance Treatment for Early Loss of B-Cell Aplasia after Tisagenlecleucel Therapy

Blood (2021) 138 (Supplement 1): 3859.

https://doi.org/10.1182/blood-2021-152344

Published: 2021

Journal Articles

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

Elad Jacoby, MD, Sara Ghorashian, FRCPath, PhD, Britta Julia Vormoor, MD, Barbara De Moerloose, MD, Nicole Bodmer, Michael Maschan, MD, Asaf David Yanir, MD, Bella Bielorai, MD, Srdan Rogosic, Olga Molostova, MD, Claudia Rossig, Amos Toren, MD PhD, Arend von Stackelberg, MD, Jean-Pierre Bourquin, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141940

Published: 2020

Journal Articles

The Enhanced Functionality of Low-Affinity CD19 CAR T Cells Is Associated with Activation Priming and Polyfunctional Cytokine Phenotype

Ilaria M. Michelozzi, PhD, Eduardo Gomez-Castaneda, PhD, Ruben V.C. Pohle, Ferran Cardoso Rodriguez, Jahangir Sufi, Pau Puigdevall, PhD, Meera Subramaniyam, Si Wei Wu, Aleks Guvenel, PhD, Sara Ghorashian, FRCPath, PhD, Martin Pule, MDPhD, Christopher J. Tape, PhD, Sergi Castellano, PhD, Persis J Amrolia, FRCP, FRCPath, PhD, Alice Giustacchini, PhD

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-141249

Published: 2020

Journal Articles

Nanobody Based Tri-Specific Chimeric Antigen Receptor to Treat Acute Myeloid Leukaemia

Warren Hazelton, MSc, Sara Ghorashian, FRCPath, PhD, Martin Pule, MDPhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-141214

Published: 2020

Journal Articles

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-138438

Published: 2020

Journal Articles

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham, Vasudha Rao, Jack Bartram, Philip Ancliff, Sara Ghorashian, David O’Connor, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Michelle Cummins, Andrea Malone, Katharine Patrick, Denise Bonney, Beki James, Brenda Gibson, Ajay Vora

Blood (2020) 135 (17): 1501–1504.

https://doi.org/10.1182/blood.2019004008

Published: 2020

Journal Articles

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Blood (2019) 134 (Supplement_1): 225.

https://doi.org/10.1182/blood-2019-125009

Published: 2019

Journal Articles

Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans

Christine Rivat, Natalia Izotova, Rachel Richardson, MSc, Danilo Pellin, Rachael Hough, Robert Wynn, MD, Kim Champion, Andre Lopes, Sara Ghorashian, FRCPath, PhD, Martin Pule, Adrian J. Thrasher, MBBS, PhD FMedSci, Luca Biasco, PhD, Persis J Amrolia, FRCP, FRCPath, PhD

Blood (2019) 134 (Supplement_1): 52.

https://doi.org/10.1182/blood-2019-125916

Published: 2019

Journal Articles

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Blood (2019) 134 (Supplement_1): 1995.

https://doi.org/10.1182/blood-2019-124404

Published: 2019

NARROW

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

A Single Centre Cohort Study of Monitoring B Cell Populations in the Bone Marrow and Peripheral Blood Post Tisagenlecleucel Therapy of Relapsed/Refractory Acute Lymphoblastic Leukaemia

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Routine Whole Genome Sequencing for All Children with Hematological Malignancies Defines a New Standard of Care - Data of the First 152 Cases from the NHS England Genomic Medicine Service

Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Siglec-6 CAR T: magic bullet for a moving target

Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia Administered Inotuzumab Pre CAR-T Therapy

A High Sensitivity aCD22 CAR Combined with aCD19 CAR to Generate Dual Targeting CAR T Cells for the Treatment of r/r B-ALL

ALL Maintenance Treatment for Early Loss of B-Cell Aplasia after Tisagenlecleucel Therapy

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

The Enhanced Functionality of Low-Affinity CD19 CAR T Cells Is Associated with Activation Priming and Polyfunctional Cytokine Phenotype

Nanobody Based Tri-Specific Chimeric Antigen Receptor to Treat Acute Myeloid Leukaemia

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Blinatumomab for infant acute lymphoblastic leukemia

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only